231 related articles for article (PubMed ID: 2309001)
1. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
[TBL] [Abstract][Full Text] [Related]
3. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
Peters RH; Jollow DJ; Stuart RK
Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
[TBL] [Abstract][Full Text] [Related]
5. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
Vogler WR; Olson AC; Berdel WE; Okamoto S; Glasser L
Prog Clin Biol Res; 1990; 333():1-18; discussion 19-20. PubMed ID: 2308973
[TBL] [Abstract][Full Text] [Related]
6. Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts.
Yamazaki T; Sato Y; Sieber F
Exp Hematol; 1997 Jul; 25(7):629-37. PubMed ID: 9216739
[TBL] [Abstract][Full Text] [Related]
7. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
[TBL] [Abstract][Full Text] [Related]
8. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
Lopez M; Mary JY; Sainteny F
Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of colony-forming unit assays for engraftment and leukemia-free survival after transplantation of chemopurged syngeneic bone marrow in rats.
Wiley JM; Yeager AM
Exp Hematol; 1991 Mar; 19(3):179-84. PubMed ID: 1704843
[TBL] [Abstract][Full Text] [Related]
10. Photoradiation methods for purging autologous bone marrow grafts.
Gulati S; Atzpodien J; Lemoli RM; Shimazaki C; Clarkson B
Prog Clin Biol Res; 1990; 333():87-102. PubMed ID: 2137934
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
[TBL] [Abstract][Full Text] [Related]
12. Prediction of the ability to purge tumor from murine bone marrow using clonogenic assays.
Jones RJ; Colvin OM; Sensenbrenner LL
Cancer Res; 1988 Jun; 48(12):3394-7. PubMed ID: 3285994
[TBL] [Abstract][Full Text] [Related]
13. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging.
Beran M; Andersson BS; Wang Y; McCredie KB; Farquhar D
Cancer Res; 1988 Jan; 48(2):339-45. PubMed ID: 3275495
[TBL] [Abstract][Full Text] [Related]
14. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z).
Slavin S; Mumcuoglu M; Landesberg-Weisz A; Kedar E
Bone Marrow Transplant; 1989 Sep; 4(5):459-64. PubMed ID: 2676042
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging.
Peters RH; Brandon CS; Avila LA; Colvin OM; Stuart RK
Cancer Chemother Pharmacol; 1989; 23(3):129-34. PubMed ID: 2924369
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxic interaction between 5-fluorouracil and 4-hydroperoxycyclophosphamide against L1210 murine leukemic cells: applicability to ex vivo purging.
Mao XY; Higashigawa M; M'Soka T; Shimono Y; Nagata T; Inamochi H; Cao DC; Hori H; Kawasaki H; Sakurai M
Cancer Invest; 1999; 17(7):486-93. PubMed ID: 10518193
[TBL] [Abstract][Full Text] [Related]
17. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
Kühl JS; Sikic BI; Blume KG; Chao NJ
Exp Hematol; 1992 Oct; 20(9):1048-54. PubMed ID: 1468539
[TBL] [Abstract][Full Text] [Related]
18. Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide.
Rowley SD; Colvin OM; Stuart RK
Exp Hematol; 1985 May; 13(4):295-8. PubMed ID: 3987832
[TBL] [Abstract][Full Text] [Related]
19. Suitability of a new stable acetal analogue of aldoifosphamide for purging leukemic cells from human bone marrow.
Andersson BS; Wang YQ; McCredie KB; Farquhar D
Leukemia; 1990 Jun; 4(6):435-40. PubMed ID: 2359343
[TBL] [Abstract][Full Text] [Related]
20. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Lemoli RM; Gulati SC
Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
